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Purpose. Sarcoidosis is a systemic granulomatous disease with unknown etiology. Many clinical presentations have been reported,
and acute disease needs to be distinguished from subacute and chronic disease. The unpredictable clinical course of the disease
prompted us to evaluate the clinical utility of biomarker serum detection in sarcoidosis follow-up. Methods. Serum
concentrations of chitotriosidase, ACE, KL-6, and lysozyme were analyzed by different methods in a population of 74
sarcoidosis patients (46 on steroid therapy at sampling) regularly monitored at Siena Sarcoidosis Regional Referral Centre and
in a group of controls with the aim of comparing their contribution to clinical management of sarcoidosis patients. Results.
KL-6 concentrations were significantly elevated in sarcoidosis patients with lung fibrosis and were significantly correlated with
DLco and CPI score, while chitotriosidase was significantly higher in patients with extrapulmonary localizations. With a cut-off
value of 303.5 IU/ml, KL-6 showed the best sensitivity (78%), while chitotriosidase reported the best specificity (85%) among the
biomarkers. Conclusions. KL-6 is a reliable biomarker of fibrotic lung involvement in sarcoidosis patients. Among biomarkers,
KL-6 showed the best sensitivity and serum chitotriosidase the best specificity, even in patients on chronic steroid therapy, and
seemed to correlate with extrapulmonary localizations.
1. Introduction
Sarcoidosis is a systemic granulomatous disease associated
with T lymphocyte and macrophage activation and migra-
tion into affected organs. The interaction between antigens
and APC polarizes T lymphocytes to T helper 1 phenotype
(Th1), leading to the formation of sarcoid granulomas
consisting of T cells, macrophages, and epithelioid and giant
cells [1, 2]. The course of sarcoidosis is unpredictable: remis-
sion occurs in most cases, while persistent granuloma inflam-
mation may lead to fibrotic lung disease [3–6]. Specific
biomarkers with good sensitivity and specificity are therefore
needed to predict clinical outcome and guide clinical
decisions.
Human chitotriosidase is a biomarker secreted by acti-
vated macrophages and neutrophils. Although its physiolog-
ical role is not clear, it may play a role in the hydrolysis and
degradation of chitin and chitin-like substrates [7].
Increased concentrations of chitotriosidase have been
reported in serum and BAL of patients with active sarcoid-
osis [8]. Chitotriosidase shows a correlation with radiolog-
ical stages. It may predict clinical course, steroid
responsiveness, and potential relapses of the disease [9].
However, it is not clear whether chitotriosidase is reliable
in the management of sarcoidosis patients with extrapul-
monary organ involvement.
Angiotensin-converting enzyme (ACE) is an acid glyco-
protein that converts angiotensin I into angiotensin II. It is
produced by lung endothelial cells, mainly activated alveolar
macrophages [10]. It is elevated in serum and BAL of sar-
coidosis patients and its concentrations correlate with radio-
logical stages [11–13]. However, its utility as a diagnostic and
prognostic tool is limited by its low sensitivity and specificity.
ACE may be elevated in certain granulomatous disorders
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(including berylliosis and silicosis), hyperthyroidism, diabe-
tes, and other diseases [14, 15].
Lysozyme is produced by monocyte-macrophage system
and epithelioid cells involved in granuloma formation can
release this enzyme. Sarcoidosis patients show increased
concentration of lysozyme at onset. Lysozyme is regarded
more as a prognostic indicator rather than a diagnostic tool.
It has a low specificity being elevated in lung diseases such as
tuberculosis and pneumoconiosis [16, 17].
Krebs von den Lungen-6 (KL-6) is a human
high-molecular weight MUC1 mucin protein derived from
AEC. Its serum concentrations are elevated in several ILDs,
including idiopathic pulmonary fibrosis and sarcoidosis
[18–20]. In sarcoidosis, KL-6 correlates with ACE activity:
it is mainly increased in stage 2 and 3 patients with scinti-
graphic evidence of positive pulmonary accumulation [21].
High levels of serum KL-6 in sarcoidosis reflect produc-
tion of KL-6 derived from damaged or regenerating type
2 pneumocytes [22].
In this study, we compared serum levels of different
biomarkers in a cohort of patients with chronic sarcoidosis
looked for correlations with specific phenotypes, clinical
presentation, and localizations.
2. Materials and Methods
2.1. Study Population. We retrospectively enrolled 74
sarcoidosis patients (27 males (36.5%), with a mean age of
44 6 ± 7 7 years) regularly monitored at Siena Regional
Referral Centre for Sarcoidosis and ILDs. All patients were
diagnosed according to international ATS/ERS/WASOG cri-
teria. All had been in follow-up at our center for more than 2
years since diagnosis and showed a persistent chronic dis-
ease. The exclusion criteria included patients with Lofgren
syndrome, acute disease onset, spontaneous resolution, or a
follow-up of less than 2 years.
Serum sampling was performed at the enrollment: in the
same day, pulmonary function test (PFT) and chest X-ray,
with radiological staging according to Scadding criteria
[23], were performed. The radiological classification was
linked to sample detection in a standard manner according
to widely accepted criteria: stage 0, normal; stage 1, bilateral
hilar adenopathy without parenchymal involvement; stage
2, bilateral adenopathy and parenchymal infiltration; stage
3, parenchymal infiltration; and stage 4, pulmonary fibrosis
associated with sarcoidosis. All patients underwent
high-resolution CT scan of the chest (HRCT) to check for
pulmonary fibrosis. All subjects gave their informed consent
to the study, approved by the Local Ethic Committee. In
order to find a cut-off value of serum KL-6 in our population,
we collected serum samples from 25 healthy volunteers (6
males, mean age 48 ± 21 years), with no history of respiratory
diseases and not taking any drugs
2.2. Pulmonary Function Tests. The following lung function
measurements were conducted according to ATS/ERS
standard parameters [24–26], using a Jaeger Body Plethys-
mograph with corrections for temperature and barometric
pressure: forced expiratory volume in the first second
(FEV1), forced vital capacity (FVC), and diffuse lung carbon
monoxide (DLCO). All parameters were expressed as per-
centages of predicted values [27].
2.3. Clinical Phenotyping. Patients were classified on the basis
of the radiological lung involvement and sarcoidosis localiza-
tions, according to recent Genotype-Phenotype Relationship
in Sarcoidosis document (GenPhenReSa) [28], as well as
composite physiologic index (CPI) score. We calculated
CPI in every patient according to the following formula, as
previously described [29]: 91− (0 65 × percent predicted
DLCO)− (0 53 × percent predicted FVC)+ 0 34 × percent
predicted FEV1 .
Extrapulmonary localizations of disease were assessed
with organ-specific diagnostic pathways: involvements of
the liver, spleen, bone, bone marrow, extrathoracic lymph
nodes, and skin were all biopsy proven, while cardiac locali-
zation was assessed with MR imaging.
2.4. Chitotriosidase Assay. Chitotriosidase activity was
determined by a fluorimetric method using 22μM
4-methylumbelliferyl β-D-N,N′,N″-triacetylchitotriosidase
(Sigma Chemical Co.) in citrate-phosphate buffer, pH5.2;
100μl substrate was incubated for 1 h at 37°C and the
reaction was stopped with 1.4ml 0.1M glycine-NaOH
buffer, pH10.8. Fluorescence was read at 450nm with a
PerkinElmer Victor X4 fluorimeter (excitation wavelength
365 nm). Serum activity of chitotriosidase was expressed
in nmol/ml/h. Normality values were calculated according
to our previous studies [9].
2.5. ACE Assay. ACE activity was measured using a colori-
metric method (FAR srl, Verona, Italy), for determination
of ACE activity in serum. The normal range of ACE concen-
trations was 30-80 IU/l [30].
2.6. Lysozyme Assay. Lysozyme activity was measured using a
colorimetric method (FAR kit, FAR srl, Verona, Italy). The
reference value for serum lysozyme was 2.5-8mg/l [17].
2.7. Krebs von den Lungen-6 Assay. Serum KL-6 was mea-
sured by NANOPIA® KL-6 reagents assay (Sekisui Diagnos-
tics, UK). The principle of the assay is agglutination of
sialylated carbohydrate antigen in samples with KL-6 mono-
clonal antibody through the antigen-antibody reaction. The
change in absorbance is measured to determine serum
KL-6 levels. KL-6 concentrations are expressed in IU/ml.
2.8. Statistical Analysis. The data was expressed as mean ±
standard deviation M ± SD . Comparisons between groups
were performed by Mann-Whitney test and Kruskal-
Wallis test with significance set at p < 0 05. The Spearman
test was used to look for correlations between variables.
Statistical analysis and ROC curves were performed using
Statistica v 7.0 software; graphic representations of data
were conducted using GraphPad Prism 4.0 software.
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3. Results
3.1. Clinical, Radiological, and Functional Parameters.
Demographic features, pulmonary function test values, and
Scadding radiological stages of population are reported in
Table 1. As expected [31], onset mainly occurred in the 5th
decade (44 6 ± 7 7 years), prevalent in never-smoker females.
Concerning medical history, 46 patients (62%, 17 males)
were on steroid therapy at the time of serum sampling, with
an average dose of 7 07 ± 9 74mg of prednisone. Of these,
all but one were taking oral steroids for more than one year.
13 patients (3 males) were taking immunosuppressive drugs
in combination with oral steroids (12 with methotrexate, 1
with azathioprine). Among steroid-free subgroup (28
patients, 10 males), only two patients had never taken specific
therapy for sarcoidosis.
In our population, PFT parameters were in the normal
range with no significant alteration of lung volumes: 63
patients managed to perform an acceptable maneuver for
DLCO that was mildly impaired, on average.
3.2. Comparison of Biomarkers. Serum KL-6 concentration
was calculated in all patients and healthy volunteers; ACE
and lysozyme were detected in serum of all patients. Six
patients with chitotriosidase activity <10 nmol/ml/h were
suspected to have CHIT1 polymorphism and were excluded
from the analysis.
Sarcoidosis patients reported significantly higher KL-6
levels than healthy controls (573 ± 480 IU/ml vs. 267 7 ±
147 7 IU/ml, U = 344, p < 0 0001). ROC curve analysis
revealed an area under the curve (AUC) of 0.788, 78% sensi-
tivity and 73% specificity, with a cut-off of 303.5 IU/ml
(p < 0 0001). Table 1 shows the mean concentrations of
serum biomarkers in our population: the prevalence of ele-
vated KL-6, chitotriosidase, ACE, and lysozyme was 78%,
58.1%, 36.5%, and 12.1%, respectively.
No significant differences of biomarkers’ levels were
found between patients treated with steroids and those
treated with steroids and immunosuppressive therapy.
KL-6 was significantly correlated with ACE (r = 0 5;
p < 0 0001), lysozyme (r = 0 35; p = 0 001), and chitotriosi-
dase activity (r = 0 32; p = 0 004) (Figure 1).
KL-6 was significantly correlated with DLCO percentages
(r =-0.34; p = 0 006) (Figure 2(a)), but not with FVC, FEV1,
and TLC. CPI score (13 6 ± 17 4) showed a significant direct
correlation with KL-6 levels (r = 0 4; p = 0 001) (Figure 2(b)).
3.3. Organ Involvement and Phenotypes. The percentage of
sarcoidosis patients showing extrapulmonary involvement
was 43.2%. The most common extrapulmonary localiza-
tions were the skin (16 patients, 21.6%), spleen (11
patients, 14.8%), and liver (5 patients, 6.7%). Less com-
mon localizations were the eyes (3 patients, 4% of cases)
and extrathoracic lymph nodes (3 patients, 4%); CNS (2
patients 2.7% of cases) and cardiac, bone, or bone marrow
involvement (1.3% of cases). Sarcoidosis patients with
extrapulmonary involvement had significantly higher chit-
otriosidase activity than those with limited pulmonary
disease (146 6 ± 175 9 vs 72 7 ± 80 1 nmol/h/ml; p = 0 01)
(Figure 3). No other significant differences were observed
in relation with organ localizations.
In relation to GenPhenReSa phenotypes, patients with
abdominal involvement (n = 9) showed significantly higher
chitotriosidase activity than those with ocular-cardiac-
cutaneous-central nervous system (OCCC) (n = 7),
musculoskeletal-cutaneous (n = 11), and isolated pulmonary
involvement (n = 34) (221 ± 272 vs 126 ± 162 vs 162 ± 98 vs
86 ± 81, respectively; p < 0 05). No statistically significant
differences were found between KL-6, ACE, and lysozyme
levels in these subgroups.
According to radiological score, patients with fibrotic
sarcoidosis (stage 4) showed the highest concentrations of
serum KL-6 compared to the other radiological stages of
disease (p = 0 01) (Figure 4).
4. Discussion
Many biomarkers have been proposed for sarcoidosis, but
none has shown satisfactory prognostic value for identifying
relapse under therapy or vital organ localization. In this
study, we compared different sarcoidosis biomarkers. We
selected chronic disease patients in treatment for more than
1 year with clinical and demographic data compatible with
the general features of sarcoidosis reported in the literature
Table 1: Demographic features, pulmonary function test values,
radiological assessment, and biomarker assessment in sarcoidosis
population.
No. 74
Male (%) 27 (36)
Age (years) 44 6 ± 7 7
Smoking status
Former (%) 21 (28)
Current (%) 6 (8)
Never (%) 46 (62)
Radiological stages
0 0
1 7
2 33
3 12
4 22
Pulmonary function tests
FEV1 % 94 4 ± 22 06
FVC % 104 3 ± 20 2
TLC % 107 7 ± 23 2
DLCO %∗ 77 4 ± 17 6
Laboratory markers
ACE (U/l) 76 1 ± 41 9
Lysozyme (mg/l) 5 4 ± 2 5
Chitotriosidase (nmol/ml/h) 105 6 ± 135 8
KL-6 (U/ml) 573 ± 480 7
Data are expressed as media ± SD. ∗Parameter available only in 63 patients.
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Figure 1: KL-6 correlations with ACE, chitotriosidase, and lysozyme. ∗∗∗r = 0 5154, p < 0 0001; ∗r = 0 3238, p = 0 0049; ∗∗r = 0 3750,
p = 0 001.
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Figure 2: (a) Correlation of KL-6 and DLCO percentages. R =-0.34, p = 0 0006. (b) Correlation between CPI score and KL-6 levels. CPI:
composite physiologic index. r = 0 4, p < 0 0001.
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[1, 2]. We included KL-6 in the list of biomarkers, although
this protein has been studied in IPF and little data are avail-
able on its role in sarcoidosis. Our interest in KL-6 was
related to its reported correlation with severe fibrotic lung
involvement and poor survival [32]. Chitotriosidase, ACE,
and lysozyme showed a lower prevalence in our population
than previously observed, probably because most patients
were on long-term systemic treatment with steroids and did
not show signs of active disease at the time of serum sam-
pling. On the contrary, KL-6 showed a good sensitivity and
specificity in our population, with a cut-off value of
303.5 IU/ml. To our knowledge, this is the first study to
investigate a specific cut-off value of KL-6 in chronic sarcoid-
osis versus a group of healthy controls; however, this was not
the main aim of the study and the data needs to be validated
in a wider cohort of patients. Our findings confirmed the
predictive value of KL-6 for fibrotic lung involvement and
functional impairment in ILD sarcoidosis patients already
reported by Miyoshi et al. [20]; however, our study is the first
one that shows a significant correlation between a serum
biomarker, KL-6, and pulmonary fibrotic lung involvement
in sarcoidosis patients, quantified by CPI index. Moreover,
this finding is further confirmed by a significant correlation
with DLCO percentages, sustaining the potential utility of
KL-6 measurements to evaluate sarcoidosis severity in the
clinical management of these patients. These data were
consistent regardless therapy status, suggesting a chronic
macrophage activation unresponsive to steroid therapy, in
particular in those patients with fibrotic lung disease. No
significant differences of KL-6 expression were found among
clinical phenotypes and/or extrapulmonary localizations,
indicating that KL-6 can be considered reliable only for
pulmonary involvement of disease. Positive correlations were
detected among sarcoidosis biomarkers, including ACE,
lysozyme, chitotriosidase, and KL-6 that can therefore be
included in the list of prognostic indicators.
On the other hand, chitotriosidase proved more sensitive
than ACE, lysozyme, and KL-6 even in patients under sys-
temic treatment; it also seems to be the only biomarker that
can reflect extrathoracic involvement, according to the recent
GenPhenReSa clinical phenotype classification. In particular,
its expression is more pronounced in patients with abdomi-
nal organ localizations (the liver and spleen, in our popula-
tion), probably due to an overexpression by activated
resident macrophages; this data suggests that chitotriosidase
may be a reliable marker of activation of reticuloendothelial
system in sarcoidosis, as previously reported in patients with
lysosomal storage disease [33]. No studies are available on
chitotriosidase prognostic value in splenic and hepatic sar-
coidosis localizations and this is a relevant novelty of this
study. Unlike KL-6, chitotriosidase activity seems not to be
correlated with the severity of sarcoid pulmonary involve-
ment or functional impairment, suggesting that different pat-
terns of macrophage activation may be present in respiratory
system of sarcoidosis patients and influence biomarkers’
expression [34].
In conclusion, patients with chronic sarcoidosis, severe
extrapulmonary involvement, or stage 4 fibrotic impairment
represent an important target requiring the identification of
reliable prognostic biomarkers to predict disease relapse
and response to systemic treatment.
Based on these preliminary results, high levels of
chitotriosidase and KL-6 (and not ACE or lsysozyme) were
observed in chronic sarcoidosis patients, regardless therapy.
Chitotriosidase activity was significantly higher in patients
with a multiple organ involvement, showing a promising reli-
ability for evaluation multisistemic sarcoidosis. On the con-
trary, KL-6 levels correlated with fibrotic lung involvement,
CPI score, and reduced DLCO percentages suggest a poten-
tial role as a marker of severity of pulmonary sarcoidosis.
Interestingly, these findings were reported in a population
of chronic multiorgan sarcoidosis patients, including those
on therapy, expanding the reliability of chitotriosidase and
KL-6 also in this setting.
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